Slide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
|
|
- Valentine Lloyd
- 5 years ago
- Views:
Transcription
1 Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University of Toronto Slide 2 Maintenance Therapy Options Chemotherapy Continue same doublet chemotherapy Continue same single agent chemotherapy Switch to new single agent chemotherapy Targeted agents Continue targeted agent used with chemotherapy Switch to a new targeted agent Add a new (2 nd ) targeted agent Slide 3 Maintenance Chemotherapy Continuing Same First-Line Single Agent Induction Chemotherapy Without the Platinum Analogue
2 Slide 4 Advanced NSCLC Gemcitabine Maintenance Therapy Stage IV NSCLC (n=352) CR / PR / SD after cisplatin/gemcitabine (n=26) R A N D O M IZ E Primary endpoint: median time to progression Maintenance gemcitabine 125 mg/m 2 day 1, 8 Q3W plus BSC (No cisplatin) BSC only Brodowicz et al, Lung Cancer 26; 52: Slide 5 Advanced NSCLC Gemcitabine Maintenance Therapy Progression-Free Survival PFS from the date of starting first-line chemotherapy P<.1 PFS from the date of randomiztion to maintenance P<.1 Overall survival: 13. mos vs 11. mos, p=.19 Brodowicz et al, Lung Cancer 26; 52: Slide 6 POI-1-3-5: Phase III Study of Maintenance Gemcitabineafter Standard First-Line Therapy in Advanced NSCLC Stage IIIb/IV NSCLC PS - 2 N=6 Gem d 1,8 + carbo AUC 5 d1 X 4 cycles PD Off study CR, PR, or SD Primary endpoint: OVERALL Survival R Gemcitabine 1 mg/m 2 d 1,8 + BSC 21 day cycle N=332 Until progression BSC
3 Slide 7 Progression-Free Survival HR=1.9 ( ) P =.575 BSC 7.7 mos Gemcitabine 7.4 mos Belani et al. Proc ASCO, 21 Slide Overall Survival HR=.97 (72-1.3) P = BSC 9.3 mos Gemcitabine 8. mos Overall Survival (months) Belani et al. Proc ASCO, 21 Slide 9 IFCT-GFPC 52 Study Design PD: off Maintenance Progression: treatment 2 nd line A Observation PD Pem Cisplatin Objective N=155 gemcitabine response or R* B x 4 cycles Gemcitabine PD Pem stable disease N=464 N=834 N=154 C Erlotinib PD Pem NSCLC N=155 Stage IIIB wet IV Tumor tissue PS -1, 18-7 years EGFR IHC Primary endpoint: PFS Asymptomatic brain EGFR mutation mets allowed Induction chemo: cisplatin 8 mg/m 2 d1 + gemcitabine 1,25 mg/m 2 d1, d8 Arm B: gemcitabine 1,25 mg/m 2 d1, d8 Q 3 wks Arm C: erlotinib 15 mg PO daily
4 Slide 1 Probability PFS by Independent Review Gemcitabine vs Observation Median PFS, months PFS at 6 months, % HR=.55 (.43.7) Log-rank test, p<.1 Observation N=152 Observation Gemcitabine Gemcitabine N= PFS at 3 months, % Time (months) Perol et al. Proc ASCO, 21 Slide 11 PARAMOUNT Study Design Induction treatment period (unblinded): Four cycles of pemetrexed (5 mg/m 2, Day 1) + cisplatin (75 mg/m 2, Day 1)* (approximately 9 patients) Patients who have a documented response of CR, PR, or SD and have an ECOG PS of or 1 Blinded Pemetrexed 5 mg/m 2 Placebo + BSC* maintenance + BSC* (D1, q21d) period (D1, q21d) until disease progression until disease progression 2:1 (approximately 372 (approximately 186 patients) randomization patients) *Patients received folic acid, vitamin B 12, and dexamethasone. Slide 12 PARAMOUNT: Investigator Assessed PFS (from Maintenance) Survival Probability Pemetrexed: median = 4.1 mos ( ) Placebo: median =2.8 mos ( ) Log-rank P=.6 Unadjusted HR:.62 ( ) Time (Months) Paz-Ares et al. Proc World Lung Conference, 211
5 Slide 13 Survival Probability PARAMOUNT: Independently Reviewed PFS (472/539) 1. Pemetrexed: median =3.9 mos (3.-4.2).9 Placebo: median =2.6 mos ( ).8 Log-rank P=.2.7 Unadjusted HR:.64 ( ) Time (Months) Paz-Ares et al. Proc World Lung Conference, 211 Slide 14 PARAMOUNT: Subgroup PFS HRs All Randomized Patients (N=539) Stage IV (n=489) Stage IIIB (n=5) Induction Response CR/PR (n=242) Induction Response SD (n=28) Pre-randomization PS 1 (n=366) Pre-randomization PS (n=17) Non-smoker (n=116) Smoker (n=419) Male (n=313) Female (n=226) Age <7 (n=447) Age 7 (n=92) Age <65 (n=35) Age >65 (n=189) Other Histologic Diagnosis (n=32) Large Cell Carcinoma (n=36) Adenocarcinoma (n=471) Favors Pemetrexed Treatment Hazard Ratio (95% CI) Favors Placebo PFS results were internally consistent; benefit was seen across all subgroups Slide 15 Survival Probability PARAMOUNT: Independently Reviewed PFS (472/539) 1. Pemetrexed: median =3.9 mos (3.-4.2).9 Placebo: median =2.6 mos ( ).8 Log-rank P=.2.7 Unadjusted HR:.64 ( ) Survival Results Awaited Time (Months) Paz-Ares et al. Proc World Lung Conference, 211
6 Slide 16 PointBreak: Pem/Carbo/Bev Followed by Maintenance Pem/Bev vs Paclitaxel/Carbo/Bev in Stage IIIB or IV Nonsquamous NSCLC Determination of eligibility R A N D O M I Z A T IO N Pem 5mg/m² q 21 D Carb AUC 6 q 21 D Bev 15 mg/kg q 21 D Vitamin Supplement as per label N=45 Pac 2 mg/m² q21 D Carb AUC 6 q 21 D Bev 15 mg/kg q 21 D Premedication as per label N=45 Induction Therapy Up to 4 21 day cycles Pts CR, PR, or SD after 4 cycles of induction therapy continue on maintenance therapy Patel JD et al. Clinical Lung Cancer 29;1(4): Pem 5mg/m² q 21 D Bev 15 mg/kg q 21 D Vitamin supplement as per label Bev 15 mg/kg q 21 D Maintenance Therapy Until PD or treatment discontinuation Post- Discontinuation Follow-up Pts with PD FU every 9 days until death Pts without PD FU every 6 weeks until PD; thereafter, followup every 9 days until death Slide 17 Maintenance Chemotherapy Switching to a New Chemotherapy Agent in Responding and Stable Patients (Usually a Single Agent) Slide 18 Immediate versus Delayed Docetaxel Chemonaϊve Stage IIIb/IV NSCLC N = 562 GC Phase N = 552 (388 received 4 cycles) ORR 29% SD, PR, CR N = 37 Immediate N = 153 Randomized Immediate Treated N = 142 Treated Off Study N = 245 Delayed N = 154 Delayed Treated N = 91 Fidias et al. J Clin Oncol 27: 591, Feb, 29
7 Survival Probability Proportion Surviving Slide 19 Progression-Free Survival Total Randomized Population Please note: the PFS curves only showed up to Immediate Delayed LR 24 months since very few patients left without PD/survival 24 months (n=153) after randomization. (n=154) p-value Median PFS months (95% CI) 6.5 (4.4, 7.2) 2.8 (2.6, 3.4) < month PFS, % (95% CI) 2% (13, 26) 9% (5, 14). therapy Delayed Immediated Progression Free Survival (months) I: D Patients at Risk Slide 2 Overall Survival Total Randomized Population Median OS, months (95% CI) Immediate (n=153) 11.9 (1., 13.7) Delayed (n=154) 9.1 (8., 11.2) LR p-value mo survival (95% CI) 48.5% (39.9, 57.1) 38.3% (3., 46.5) Overall Survival Time (in Months) Patients at I: D: Risk Is this negative for survival benefit or under-powered?? Slide 21 JMEN: Phase III Study of Maintenance Pemetrexed after Standard First-Line Therapy in Advanced NSCLC Stage IIIB or IV NSCLC who has not progressed after 4 cycles of a standard chemotherapy R Pemetrexed 5 day 1 N = 66 Patients Placebo + day 1 Primary objective: PFS, Superiority design Secondary objectives: RR, OS, TTPD, TWQ (Time to Worsening QOL), QOL based on LCSS
8 Progression-free Probability Slide 22 JMEN: Progression-Free Survival 1. N=581 HR=.599 (95% CI:.49.73) p <.1 Pemetrexed: 4.4 mos (95% CI: ) Placebo: 1.97 mos (95% CI: ) Time (months) 24% censored Ciuleanu, et al. Presented at: Annual Meeting of the American Society of Clinical Oncology, June 2, 28; Chicago, IL. Slide 23 Overall Survival, All Randomized Patients HR.79, CI , p=.12 Ciulanu et al. Lancet, 29 Slide 24 Non-Squamous Subset PFS and OS in the non-squamous subset PFS HR.44, p<.1 OS HR.7, p= vs 11.7 months for adeno Ciulanu et al. Lancet, 29
9 Slide 25 Meta-Analysis of Continuation vs Switch Maintenance Population HR PFS P HR OS P All.84 < Switch.77 < Continuation Chemotherapy.87 < EGFR Rx Behera M. Proc ASCO, Abst 7553, 211 Slide 26 Maintenance Therapy With Molecularly Targeted Agents Continuation of the molecularly targeted agent after chemotherapy is completed Introduction of a new molecularly targeted agent Slide 27 Continuation of the Molecularly Targeted Agent After Chemotherapy is Completed Angiogenesis Inhibitors Bevacizumab Other angiogenesis inhibitors
10 Slide 28 ATLAS: Bevacizumab +/- Erltoinib Maintenance After First-Line Treatment Chemotherapy naïve stage IIIb/IV non-squamous NSCLC Bevacizumab plus chemotherapy* PD or significant toxicity Non-PD Bevacizumab + Erlotinib 1:1 Bevacizumab + placebo PD PD Off study Erlotinib Off study PI: Dr W Navarro (USA) Primary endpoint: PFS AVG3671g (phase IIIb) Bevacizumab 15mg/kg every 3 weeks; Erlotinib 15mg/day *Either carboplatin/paclitaxel, carboplatin/gemcitabine or carboplatin/docetaxel Slide 29 PointBreak: Pem/Carbo/Bev Followed by Maintenance Pem/Bev vs Paclitaxel/Carbo/Bev in Stage IIIB or IV Nonsquamous NSCLC Determination of eligibility R A N D O M I Z A T IO N Pem 5mg/m² q 21 D Carb AUC 6 q 21 D Bev 15 mg/kg q 21 D Vitamin Supplement as per label N=45 Pac 2 mg/m² q21 D Carb AUC 6 q 21 D Bev 15 mg/kg q 21 D Premedication as per label N=45 Induction Therapy Up to 4 21 day cycles Pts CR, PR, or SD after 4 cycles of induction therapy continue on maintenance therapy Patel JD et al. Clinical Lung Cancer 29;1(4): Pem 5mg/m² q 21 D Bev 15 mg/kg q 21 D Vitamin supplement as per label Bev 15 mg/kg q 21 D Maintenance Therapy Until PD or treatment discontinuation Post- Discontinuation Follow-up Pts with PD FU every 9 days until death Pts without PD FU every 6 weeks until PD; thereafter, followup every 9 days until death Slide 3 Maintenance Therapy With Oral Angiogenesis Inhibitors Randomized trials performed with numerous agents administered with chemotherapy All continued oral AI when chemotherapy stopped (in the absence of toxicity) Until there is a positive trial of an oral AI, this question is of academic interest only
11 Slide 31 CALGB 367: Sunitinib Maintenance Therapy Post Chemotherapy Phase III, randomized, placebo-controlled trial Planned randomization: 156 patients Patients with untreated stage IIIB/IV NSCLC and ECOG PS 1 Four cycles of platinum-based chemotherapy* Randomization of responding patients or patients with stable disease stratified by prior treatment with/without bevacizumab Sunitinib 37.5 mg/day Placebo 1 Endpoint - PFS *Platinum-based regimen may include carboplatin/cisplatin plus paclitaxel, docetaxel, vinorelbine or gemcitabine with or without bevacizumab (bevacizumab discontinued after four cycles) At progression, patients receiving placebo may cross over to the sunitinib arm Continue until disease progression Planned follow-up: 1 year Slide 32 EORTC 892: Pazopanib Maintenance Therapy Post Chemotherapy Phase III, randomized, placebo-controlled trial Planned randomization: 54 patients Patients with untreated stage IIIB/IV NSCLC and ECOG PS 2 Four cycles of platinum-based chemotherapy* Randomization of responding patients or patients with stable disease Pazopanib 8mg/day Continue until disease progression Placebo 1 Endpoint - OS Slide 33 Continuation of the Molecularly Targeted Agent After Chemotherapy is Completed EGFR Monoclonal Antibodies Cetuximab
12 Proportion Without Event Slide 34 Introduction of Switch Maintenance Therapy with EGFR TKIs ATLAS SWOG 23 WJTOG-23 (EORTC 821) SATURN INFORM Slide 35 ATLAS: Bevacizumab +/- Erltoinib Maintenance After First-Line Treatment Chemotherapy naïve stage IIIb/IV non-squamous NSCLC Bevacizumab plus chemotherapy* PD or significant toxicity Non-PD Bevacizumab + Erlotinib 1:1 Bevacizumab + placebo PD PD Off study Erlotinib Off study PI: Dr W Navarro (USA) Primary endpoint: PFS AVG3671g (phase IIIb) Bevacizumab 15mg/kg every 3 weeks; Erlotinib 15mg/day *Either carboplatin/paclitaxel, carboplatin/gemcitabine or carboplatin/docetaxel Slide 36 ATLAS: Progression-Free Survival (ITT population, investigator assessment) 1..8 Bev + Placebo (n=373), Median 3.75 mo Bev + Erlotinib (n=37), Median 4.76 mo HR=.722 ( ) Log-rank P= Progression-Free Survival (months) No. of patients at risk: Bev + Placebo Bev + Erlotinib
13 Proportion Without Event Slide 37 ATLAS: Progression-Free Survival (ITT population, investigator assessment) October 15, 29, Bev Roche + Placebo has (n=373) Bev + Erlotinib (n=37) communicated to OSI that an exploratory ATLAS HR=.722 data ( ) sweep Log-rank P=.12 for survival was not positive. OS was a 2 endpoint and the study was not powered for OS!!!!! Progression-Free Survival (months) No. of patients at risk: Bev + Placebo Bev + Erlotinib Slide 38 ATLAS: PFS K-M Curves by EGFR Mutation Status EGFR Wild-Type EGFR Mutant HR =.85 (95% CI: ) Log-rank P=.262 HR =.439 (95% CI: ) Log-rank P=.137 Johnson et al. ESMO 29 Slide 39 SWOG 23 (Update): Schema Definitive Tx Cis 5 mg/m 2 Days 1, 8, 29, 36 Etop-16 5 mg/m 2 Days 1-5, XRT Gy/d, Total 61 Gy Consolidation Docetaxel 75 mg/m 2 x 3 cycles R A N D O M I Z A T I O N Maintenance Placebo Gefitinib 5 mg/day 25 mg/day (5-1-3) 1 o end point: overall survival; 2 o end points: PFS, toxicity, and correlative science Maintenance therapy could continue for a maximum of 5 years Stratification factors: IIIA vs IIIB; measurable vs non-measurable disease; squamous vs non-squamous
14 Progression-Free Survival, % Overall Survival, % Slide 4 SWOG 23 (Update): Survival Progression-Free Survival Median N Events (mo) Gefitinib Placebo Gefitinib Placebo Overall Survival Median n Events (mo) Yr 2 Yr OS OS 73% 46% 81% 59% P= P= Median Follow-up Time: 27 Months Months After Randomization Months After Randomization Kelly K et al. J Clin Oncol 26: 245, 28 Slide 41 WJTOG -23: Maintenance with Gefitinib in Patients with NSCLC IIIB/IV NSCLC PS -1 (n=64) Stratify Institution Histology Stage Chemo R A N D O M I Z E 1st-line platinum-based chemotherapy x 6 cycles 1st-line platinum-based chemotherapy x 3 cycles Gefitinib 25 mg/d 1 Endpoint Overall Survival Designed to detect a 3 mo difference from 9 to 12 mos Slide 42 WJTOG-23: Survival Results Overall Survival MST: 12.9 m vs 13.7 m HR:.86, p=.11 Median PFS MST: 4.3 m vs 4.6 m HR:.67, p<.1 Takeda et al. J Clin Oncol 28: 753, 21
15 Slide 43 WJTOG-23: Post-Study Therapy EGFR TKI at any time 54% 75% Takeda et al. J Clin Oncol 28: 753, 21 Slide 44 WJTOG-23: Post-Study Therapy MST in Non-smoking patients with adenocarcinoma Arm A 23.5 months Arm B 25.1 months >75% of these patients on Arm A received an EGFR TKI at the time of progression Takeda et al. J Clin Oncol 28: 753, 21 Slide 45 SATURN: First-line Phase III Erlotinib Maintenance Trial in Patients with NSCLC 1 st -line IIIB/IV NSCLC (n=1,7) Collect tissue 1st-line platinum-based chemotherapy x 4 cycles PD patients enter the 2nd-line study TITAN Stratify for EGFR IHC Placebo CR/PR/SD (n=85) Erlotinib Treatment to PD, unacceptable toxicity or death 1 Endpoint PFS Overall: 25% better EGFR IHC+: 3% better
16 OS probability Slide 46 SATURN: PFS in All Patients (ITT) PFS probability 1..8 Erlotinib Placebo PFS at 12 wks (%) 53 4 PFS at 24 wks (%) HR=.71 (.62.82) Log-rank p<.1 P< Time (weeks) Erlotinib (n=437) Placebo (n=447) Slide Saturn: OS in all patients (ITT) HR=.81 (.7.95) Log-rank p=.88 Erlotinib (n=438) Placebo (n=451) Time (months) *OS is measured from time of randomisation into the maintenance phase; ITT = intent-to-treat population Slide 48 EORTC 821 Closed early Gafaar et al. J Clin Oncol 28: (Suppl) Abst 7518, 21
17 Slide 49 EORTC 821 HR=.61, p=.2 HR=.81, p=.2 Gafaar et al. J Clin Oncol 28: (Suppl) Abst 7518, 21 Slide 5 IFCT- GFPC 52 study design PD: off Maintenance Progression: treatment 2 nd line A Observation PD Pem Cisplatin Objective N=155 gemcitabine response or R* B x 4 cycles Gemcitabine PD Pem stable disease N=464 N=834 N=154 C Erlotinib PD Pem NSCLC N=155 Stage IIIB wet IV Tumor tissue PS -1, 18-7 years EGFR IHC Primary endpoint: PFS Asymptomatic brain EGFR mutation mets allowed Induction chemo: cisplatin 8 mg/m 2 d1 + gemcitabine 1,25 mg/m 2 d1, d8 Arm B: gemcitabine 1,25 mg/m 2 d1, d8 Q 3 wks Arm C: erlotinib 15 mg PO daily Slide 51 Probability IFCT- GFPC 52 : PFS Erlotinib vs Observation PFS at 6 months, 8.6 % 16.3 % HR=.82 (.73.93) Log-rank test, p=.2 Observation N=152 Observation Erlotinib Erlotinib N=153 Median PFS, 1.9 mo 2.9 mo PFS at 3 months, 3.3 % 35.3 % Time (months) PFS is measured from time of randomisation into the maintenance phase
18 ORR (%) DCR (%) Probability of PFS (%) Slide 52 INFORM: Study Design Patients Age 18 years Completed 4 cycles of first-line platinum-based chemotherapy without PD or unacceptable toxicity Life expectancy 12 weeks WHO PS -2 Measurable Stage IIIB/IV disease Gefitinib (25 mg/day) 1:1 randomization Placebo (once daily) EGFR, epidermal growth factor receptor; PD, progressive disease PS, performance status; WHO, World Health Organization Endpoints Primary Progression-free survival (PFS) Secondary Objective response rate (ORR) Disease control rate (DCR) Overall survival (OS) Quality of life Safety and tolerability Exploratory Biomarkers EGFR mutation Slide 53 INFORM: Progression-Free Survival Median PFS, months 6-month PFS rate, % 12-month PFS rate, % No. events, n (%) Gefitinib (n=148) (83.8) Placebo (n=148) (97.3) HR.42 (.33,.55); p< Time since randomization (weeks) Patients at risk : Placebo Zhang et al. Proc ASCO, 211 LBA 7511 Slide 54 ORR & DCR (RECIST; ITT Population) Odds ratio (95% CI) = 54.1 (7.17, 48); p= Gefitinib (n=148).7 Placebo (n=148) Odds ratio >1 implies a greater chance of response on gefitinib Odds ratio and p-value from logistic regression with covariates ITT, intent-to-treat; RECIST, Response Evaluation Criteria In Solid Tumors Odds ratio (95% CI) = 2.69 (1.62, 4.46); 71.6 p=.1 Gefitinib (n=148) 5.7 Placebo (n=148) Zhang et al. Proc ASCO, 211 LBA 7511
19 Overall survival (%) Slide 55 Post-discontinuation Treatments None: 49.3% Gefitinib Placebo Targeted therapy: 8.1% Chemotherapy: 39.9% Others: 24.4% None: 33.1% Targeted therapy: 31.8% Chemotherapy: 53.4% Others: 23.7% Zhang et al. Proc ASCO, 211 LBA 7511 Slide 56 INFORM: Overall Survival Gefitinib Placebo (n=148) (n=148) Median OS, months month survival rate, % month OS rate, % No. events, n (%) 79 (53.4) 93 (62.8) HR.84 (.62, 1.14); p= Patients at risk: Time (weeks) Zhang et al. Proc ASCO, 211 LBA 7511 Slide 57 Phase III H3E-CR-S131 Study Schema Eligibility NSCLC: Non-squamous histology Stage IIIb/IV Chemo-naïve (1st line) PS: -1 Never smoker or light exsmoker** Unknown, untested, inconclusive EGFR mutation status R Randomization (Stratification) Factors Gender Pemetrexed 5mg/m 2 + Cisplatin 75mg/m 2, IV x 6 cycles, q3w + Vit B12/Folic Acid Gefitinib 25mg/day PO Smoking History (Never smoker/light ex-smoker) Performance status N=226 Adenocarcinoma/Non-adenocarcinoma ** light ex-smoker: quit from smoking for 5 years and 1 pack year. CR/PR/SD PD Gefitinib 25mg/day PO Primary Endpoint: Superiority in PFS HR:.68 Secondary Endpoints: PD OS, RR, Safety, BioMarkers Translational Research: Analysis of Outcomes by EGFR Mutation status * Pre-planned, pre-specified subset analysis * Presence of activating mutation(s) in exon 18 to exon 21 of the EGFR-receptor will be confirmed by direct DNA sequencing of NSCLC tumor tissue
20 Slide 58 Meta-Analysis of Continuation vs Switch Maintenance Population HR PFS P HR OS P All.84 < Switch.77 < Continuation Chemotherapy.87 < EGFR Rx Behera M. Proc ASCO, Abst 7553, 211 Slide 59 Why Was There Such a Dramatic Difference Among The Three Trials of Maintenance Gemcitabine??? Are There Clues to Patient Selection? Slide 6 Potential Predictors of Benefit From Maintenance Therapy Chemotherapy PS Response to first-line treatment Histology EGFR TKIs EGFR expression EGFR copy EGFR mutation Histology
21 Slide 61 Survival by Performance Status Brodowicz et al, Lung Cancer 26; 52: Slide 62 Patient Demographics Maintenance Phase Maintenance Phase GEM N=128 % BSC N=127 % Median age, years Age 65 years /<65 years 61/39 59/41 Stage IIIB/IV disease 22/78 9/91 Male/Female 6/4 67/33 Caucasian/AA/Other 83/13/4 88/6/6 ECOG PS /1/2/3 /44/52/4 /43/54/4 Belani et al. Proc ASCO, 21 Slide 63 Performance Status in Other Trials JMEN - PS 2 patients not eligible IFCT 52 - PS 2 patients not eligible; only 5% of randomized patients PS 2 SATURN - PS 2 patients not eligible PARAMOUNT - PS 2 patients not eligible All the above trials were Positive!!! PointBreak - PS 2 patients not eligible
22 Survival Probability Survival Probability Slide 64 Response to First-Line Chemotherapy CR/PR versus SD Slide 65 Survival by Response to First-Line Therapy Study CR/PR SD JMEN (Non-Squam) IFCT 52 (PFS) Belani NR NR IFCT 52 (PFS).8.85 SATURN Slide Patients at Risk Survival Time (months) Pem Plac JMEN: Effect of Response to Induction Rx on OS (Non-Squamous) CR or PR Median (95% CI) Pem 14.4 (12.3, 18.2) Plac 11.7 (8.5, 15.3) HR (95% CI).81 (.58, 1.12) P = Pem 14.4 months Plac 11.4 months HR=.81, p= Median (95% CI).9 Pem 16.6 (13., 2.9).8 Plac 8.6 (7.2, 11.3).7 HR (95% CI).6.61 (.45,.83).5 P = Patients at Risk Survival Time (months) Pem Plac SD Pem 16.6 months Plac 8.6 months = 8 mo!! HR=.61, p= Eli Lilly data on file 6 2
23 Slide 67 Survival by Response to First-Line Therapy Study CR/PR SD JMEN (Non-Squam) PARAMOUNT IFCT 52 (PFS) Belani NR NR IFCT 52 (PFS).8.85 SATURN Slide 68 Selection by Histology Slide 69 PFS by Histology Study Adenocarcinoma Other JMEN (squamous) IFCT Study Adenocarcinoma Other IFCT SATURN.6.76
24 Slide 7 PFS by Histology Study Adenocarcinoma Other JMEN (squamous) IFCT Study Adenocarcinoma Other IFCT SATURN.6.76 Slide 71 Continued Doublet Chemotherapy vs Maintenance Gefitinib Takeda et al J Clin Oncol 28: 753, 21 Slide 72 Selection by Biomarkers EGFR
25 Slide 73 SATURN: PFS According to Biomarker Status All HR (95% CI).71 (.62.82) n 884 EGFR IHC+.69 (.58.82) 618 EGFR IHC.77 ( ) 121 EGFR FISH+ EGFR FISH.68 (.51.9).81 ( ) KRAS mutation+.77 ( ) 9 KRAS wild-type.7 (.57.87) 43 EGFR CA-SSR1 low EGFR CA-SSR1 high.68 (.55.85).75 (.6.92) Favours HR erlotinib Favours placebo Slide 74 SATURN: PFS According to EGFR Mutation Status HR (95% CI) N All.71 (.62.82) 884 EGFR mutation+.1 (.4.25) 49 EGFR wild-type.78 (.63.96) HR Favours Favours erlotinib placebo 328 Slide 75 SATURN OS Subgroup Analyses for EGFR IHC & EGFR Mutations All HR (95% CI) n.81 (.7.95) 889 EGFR IHC+ EGFR IHC- *EGFR mutation+ EGFR wild-type Favours HR erlotinib Favours placebo Quantitative not qualitative interaction.77 (.64.93) ( ) ( ) (.61.97) 388 * 67% of patients with EGFR mutation+ disease in the placebo arm received a second-line EGFR TKI Cappuzzo et al. Proc IASLC, 29
26 OS probability OS probability 1,,9,8,7,6,5,4,3,2,1, Slide OS in EGFR Wild-Type Groups HR=.77 (.61.97) Log-rank p= Erlotinib (wild-type) n=199 Placebo (wild-type) n= Time (months) Slide 77 SATURN: OS in EGFR Wild-Type Group With SD on 1st-line Chemotherapy Erlotinib (n=114) Placebo (n=13) HR=.65 (.48.87) Log-rank p= Time (months) OS is measured from time of randomisation into the maintenance phase Slide 78 IFCT- GFPC 52: Effect of Maintenance in EGFR IHC -ve Patients Gemcitabine vs observation HR=.42 [ ] Erlotinib vs observation HR =.86 [.63 ; 1.18] Months 464 randomized, 24 evaluable samples 127 EGFR IHC+ ; 77 EGFR IHC- Perol et al. Proc ASCO, 21
27 PFS (%) PFS (%) Slide 79 PERFORM: PFS by EGFR Mutation Status EGFR mutation-positive Gefitinib (n=15) Median PFS, 16.6 months No. events, 9 (6.%) Placebo (n=15) Median PFS, 2.8 months No. events, 15 (1.%) EGFR mutation-negative Gefitinib (n=25) Median PFS, 2.7 months No. events, 25 (1.%) Placebo (n=24) Median PFS, 1.5 months No. events, 24 (1.%) 1 HR (95% CI) =.17 (.7,.42) 1 HR (95% CI) =.86 (.48, 1.51) Time (weeks) Time (weeks) Zhang et al. Proc ASCO, 211 LBA 7511 Slide 8 Summary There is no evidence to support prolonged administration of platinum-based doublet chemotherapy Preliminary evidence suggests a possible role for maintenance docetaxel, and perhaps gemcitabine in unselected patients Pemetrexed is approved as maintenance therapy in patients with non-squamous cell cancer Slide 81 Summary (2) SATURN and the WJTOG-23 suggest a possible role for maintenance EGFR TKI therapy Major effect on PFS in patients with EGFR mutations with only modest effect on OS Although current practice is to continue monoclonal antibody therapy after completion of chemotherapy, there are no data to support this
Targeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationMaintenance Treatment for Advanced NSCLC. Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017
Maintenance Treatment for Advanced NSCLC Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017 Milestones in the Palliative Systemic Treatment of NSCLC 1990 2000 2010 2015 Platinum based Chemotherapy
More informationMaintenance Treatment of Advanced NSCLC
Maintenance Treatment of Advanced NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it UNIVERSTY OF TORINO DEPT. OF OF Maintenance /Consolidation/Sequencing
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationSao Paulo, Abril 2014
Tratamento de Manutencao e outros Sao Paulo, Abril 2014 Rogerio C. Lilenbaum, M.D. Professor of Medicine Yale Cancer Center Chief Medical Officer Smilow Cancer Hospital What Is Maintenance Therapy? Use
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationASCO Highlights Lung Cancer
ASCO Highlights Lung Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head & Neck Medical
More information11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients
Decision-Making in Non-Small Cell Lung Cancer (NSCLC): Moving from Empiric to Personalized & Molecular-based Therapy David R. Gandara, MD University of California Davis Cancer Center Disclosures Research
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationin combination with cisplatin as first-line doublet 3 as maintenance agent following non-pemetrexed platinum doublet 4
Overall survival (OS) results from PARAMOUNT study of maintenance plus best supportive care (BSC) versus plus BSC, immediately after induction with - Cisplatin, in patients with advanced Nonsquamous Non-small
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationPersonalized maintenance therapy in advanced non-small cell lung cancer
China Lung Cancer Research Highlight Personalized maintenance therapy in advanced non-small cell lung cancer Kazuhiro Asami, Kyoichi Okishio, Tomoya Kawaguchi, Shinji Atagi Department of Clinical Oncology,
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationAntiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab
Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà Milano, 11 Ottobre 2016 Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Francesco Grossi U.O.S. Tumori
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationIs there a role for maintenance therapy in advanced non-small-cell lung cancer?
Review Is there a role for maintenance therapy in advanced non-small-cell lung cancer? Cesare Gridelli*1, Paolo Maione1, Antonio Rossi1, Clorinda Schettino1, Maria Anna Bareschino1, Paola Claudia Sacco1,
More informationStage III NSCLC: Overview
Locally Advanced NSCLC: New Concepts in Combined Modality Therapy NSCLC: Stage Distribution Randeep Sangha, MD Visiting Assistant Professor UC Davis Cancer Center Sacramento, CA Stage III NSCLC: Overview
More informationMonoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs
Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Corey J Langer, MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor
More informationLUNG CANCER TREATMENT: AN OVERVIEW
LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor
More informationSecond-line treatment for advanced NSCLC
Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY DISCLOSURE OF INTEREST Speaker Bureau: Eli Lilly, MSD, BI, BMS, Roche, AZ UNIVERSITY
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationNSCLC with squamous histology: Current treatment and new options on horizon
NSCLC with squamous histology: Current treatment and new options on horizon Prof. Yasser A.Kader Professor of Oncology Faculty of Medicine, Cairo University 2015 Lung Cancer: Incidence and Mortality New
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationVEGF-Inhibitors in NSCLC. Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany
VEGF-Inhibitors in NSCLC Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Conflicts of interest Advisory Board: AstraZeneca Bristol-Myers Squibb Daiichi Sankyo Eli Lilly Merck
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationErlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
More informationAgenda. 6:30pm 7:00pm. Dinner. 7:00pm 7:15pm. NSCLC Treatment in 2014: Focus on Use of 2nd Generation TKIs in Clinical Practice.
Agenda 6:30pm 7:00pm Dinner 7:00pm 7:15pm Welcome and Introductions Natasha Leighl, MD 7:15pm 7:50pm 7:50pm 8:00pm NSCLC Treatment in 2014: Focus on Use of 2nd Generation TKIs in Clinical Practice Questions
More informationBackground. Azzoli CG et al. J Clin Oncol 2009; 2 Sandler A et al. NEJM 2006; 3
A Randomized, Open-Label, Phase III, Superiority Study of Pemetrexed(Pem) + Carboplatin(Cb) + Bevacizumab(Bev) Followed by Maintenance Pem + Bev versus Paclitaxel (Pac)+Cb+Bev Followed by Maintenance Bev
More informationPRACTICE GUIDELINE SERIES
ELLIS et al. PRACTICE GUIDELINE SERIES The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent nonsmall-cell lung cancer: a Canadian
More informationCytotoxic Maintenance Therapy in Advanced NSCLC: Update State of the Art or State of Confusion
Cytotoxic Maintenance Therapy in Advanced NSCLC: Update State of the Art or State of Confusion Corey J Langer MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor of Medicine Hematology-Oncology
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationLUNG CANCER. Başak Oyan-Uluç, MD Yeditepe University Hospital Medical Oncology. Best of ASCO, İstanbul
LUNG CANCER Başak Oyan-Uluç, MD Yeditepe University Hospital Medical Oncology Best of ASCO, İstanbul 2012 23.6.2012 Treatment of Metastatic NSCLC EGFR targetted treatments 1st line: EGFR-mutated: Afatinib
More informationPersonalized Medicine for Advanced NSCLC in East Asia
Personalized Medicine for Advanced NSCLC in East Asia - Update treatment strategy for NSCLC based on Japanese clinical practice guideline - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine,
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationLudger Sellmann 1, Klaus Fenchel 2, Wolfram C. M. Dempke 3,4. Editorial
Editorial Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer the Holy Grail in cancer treatment? Ludger Sellmann 1, Klaus Fenchel
More informationIRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca
IRESSA (Gefitinib) The Journey Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca Overview The Drug The Biomarker and Clinical Trials Sampling Lessons Learned The
More informationMaintenance therapies in advanced non-small-cell lung cancer
Review Maintenance therapies in advanced non-small-cell lung cancer Advanced non-small-cell lung cancer is treated with upfront platinum doublet chemotherapy, which produces moderate survival improvements.
More informationOverview of Lung Cancer :Perspectives from Cancer Genotype. Ji-Youn Han, MD, PhD. Center for Lung Cancer National Cancer Center
Overview of Lung Cancer :Perspectives from Cancer Genotype Ji-Youn Han, MD, PhD. Center for Lung Cancer National Cancer Center Histologic classification of lung cancer Therapeutic plateau reached with
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationTratamiento de la enfermedad avanzada en cáncer de pulmón
Tratamiento de la enfermedad avanzada en cáncer de pulmón S. Ponce Aix! S. Oncología Médica Hospital Universitario 12 de Octubre Madrid Survival by stage NSCLC Stage Distribution NSCLC Stage 5-year Survival
More informationUnderstanding Options: When Should TKIs be Considered?
Advanced Stage Squamous NSCLC: Evolution and Increasing Complexity of the Therapeutic Landscape Understanding Options: When Should TKIs be Considered? David R. Gandara, MD University of California Davis
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationTreatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line
Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line Martin Reck David F. Heigener Department of Thoracic Oncology Hospital Grosshansdorf Germany Identification of driver mutation in tumor specimens
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationTarget therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Target therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) cgridelli@libero.it First-Line Treatment of Advanced NSCLC EGFR-mutation analysis
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More informationREPORT ASCO 2018 CHICAGO: RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital KU Leuven and Leuven Lung Cancer Group
1 REPORT ASCO 2018 CHICAGO: RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital KU Leuven and Leuven Lung Cancer Group OUR 10 MESSAGE HIGHLIGHTS 1/ Advanced NSCLC 1 st line: IO
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationIs the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
More informationComparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC)
J Lung Cancer 2009;8(2):61-66 Comparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC) More effective treatments in first, second, and third-line of metastatic
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationStrategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors
Strategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors Miklos Pless Medical Oncology Kantonsspital Winterthur 2 Setting the stage. 1995: Chemotherapy works! Meta-Analysis
More informationSequencing in EGFR-Mutated NSCLC: Does Order Matter?
Sequencing in EGFR-Mutated NSCLC: Does Order Matter? Maximilian J. Hochmair, MD Otto Wagner Hospital Vienna, Austria Disclosures Honoraria: AstraZeneca, AbbVie, Pfizer, Boehringer Ingelheim, Roche, MSD,
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationImmunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
More informationTargeted therapy in lung cancer : experience of NIO-RABAT
Targeted therapy in lung cancer : experience of NIO-RABAT I.ELGHISSASSI, H.ERRIHANI Medical oncology department, NIO- RABAT 02-05- 2012, FEZ In Morocco, lung cancer is the most common tumor among men At
More informationMalignant pleural Mesothelioma: A Year In Review
Malignant pleural Mesothelioma: A Year In Review Rabab Gaafar,MD Prof. Medical Oncology NCI Cairo University National Cancer Institute Conference 2015 ASCO news in Mesothelioma Introduction ASCO news second
More informationMedical Oncology: State of the Art Therapy in Advanced NSCLC: 2011 looking toward 2015
Medical Oncology: State of the Art Therapy in Advanced NSCLC: 2011 looking toward 2015 David R. Gandara, MD University of California Davis Cancer Center Algorithm for Therapy of Advanced Stage NSCLC: 2009
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationQuale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationSuccesses and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationASCO Highlights and Controversies in advanced Lung Cancer. Torino, 11 giugno 2015
ASCO 2015 Highlights and Controversies in advanced Lung Cancer Torino, 11 giugno 2015 Paolo Bironzo AOU S Luigi Gonzaga - Orbassano Scuola di Specializzazione in Oncologia Medica Università di Torino What
More information